PhaseBio Pharmaceuticals Common Stock

PhaseBio Pharmaceuticals (PHAS) currently reports a common stock of $50K as of June 2022. That compares with $48K in the prior-year period — up 4.2% year over year. Use the charts on this page to explore PhaseBio Pharmaceuticals's common stock history and peer comparisons.

PhaseBio Pharmaceuticals's common stock increased from $48K to $50K — a 4.2% year-over-year increase (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PhaseBio Pharmaceuticals reported $50K in common stock as of June 2022. That compares with $48K in the prior-year period — up 4.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $50K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PhaseBio Pharmaceuticals, and consider following PHAS for alerts when major investors trade the stock.

PhaseBio Pharmaceuticals is classified in the Healthcare sector. On common stock, it currently shows $50K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHAS with unrelated industries.